View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 11, 2021

EMA approves fourth Covid-19 vaccine, J&J’s single-shot candidate

The European Medicines Agency (EMA) has recommended conditional marketing authorisation for Johnson & Johnson (J&J) subsidiary Janssen’s Covid-19 vaccine.

By Allie Nawrat

The European Medicines Agency (EMA) has recommended conditional marketing authorisation for Johnson & Johnson (J&J) subsidiary Janssen’s Covid-19 vaccine.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Janssen’s Covid-19 vaccine is the fourth to be recommended for use in adults in the EU; it follows vaccines produced by Pfizer/BioNTech, Moderna and AstraZeneca/Oxford. Like the AstraZeneca/Oxford vaccine, it is an adenovirus product and relies on Janssen’s proprietary AdVac platform.

The J&J vaccine is the first approved jab that is designed to be effective after a single dose. The other approved vaccines require two doses spaced over a number of weeks for optimal immunisation.

The next step towards authorisation is for the European Commission (EC), the EU’s executive body, to confirm the approval. European Commissioner for health and Food Safety Stella Kyriakides tweeted:

The recommendation came after a thorough evaluation by the EMA’s Committee for Medicinal Products for Human Use of clinical trial data submitted by J&J in December. The committee determined that the data for the vaccine was robust and met the criteria for efficacy, safety and quality.

In the Phase III ENSEMBLE study, which was carried out in the US, South Africa, as well as countries across Latin America, Janssen’s Covid-19 vaccine was found to be 67% effective at preventing symptomatic Covid-19 and 85% effective at preventing severe disease.

EMA executive director Emer Cooke said: “With this latest positive opinion, authorities across the European Union will have another option to combat the pandemic and protect the lives and health of their citizens.”

J&J chief scientific officer and vice-chairman of the executive committee Paul Stoffels commented: “The EMA’s recommendation is a landmark moment for J&J and for the world.

“Now, as we await a decision on the use of our single-dose COVID-19 vaccine in the European Union, we remain confident that the J&J vaccine will prove a critical tool for fighting this pandemic.”

Janssen’s Covid-19 has already received emergency use authorisations in the US and Canada. J&J has also submitted rolling review submissions in other parts of the world and is seeking emergency use listing with the World Health Organization.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology